Prescribing practices and morning blood pressure control: Results of a large-scale, primary-care study conducted in Germany

Journal of Human Hypertension

Volumn 22, Issue 4, 2008, Pages 295-297

  Lemmer, B ^a   Middeke, M ^b   Schaaf, B ^c   Eckes, L ^d  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b Blood Pressure Institute   (Germany)

^c Gesellschaft für Statistik wissenschaftliche Information und Kommunikation mbH   (Germany)

^d BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT;

ADULT; ARTICLE; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CIRCADIAN RHYTHM; COMBINATION CHEMOTHERAPY; GENERAL PRACTICE; GENERAL PRACTITIONER; GERMANY; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MONOTHERAPY; PRESCRIPTION; PRIMARY MEDICAL CARE; QUESTIONNAIRE;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; GERMANY; HUMANS; HYPERTENSION; MIDDLE AGED; MORBIDITY; PRESCRIPTIONS, DRUG; PRIMARY HEALTH CARE; TREATMENT OUTCOME;

EID: 41049086374     PISSN: 09509240     EISSN: 14765527     Source Type: Journal    
DOI: 10.1038/sj.jhh.1002326     Document Type: Article

References (11)

1. Wolf-Maier K, Cooper RS, Kramer H, Banegas JR, Giampaoli S, Joffres MR et al. Hypertension treatment and control in five European countries, Canada, and the United States. Hypertension 2004; 43 10-17.
2. Lemmer B. The importance of circadian rhythms on drug response in hypertension and coronary heart disease - from mice and man. Pharmacol Ther 2006; 111: 629-651.
3. American Society of Hypertension. Recommendations for routine blood pressure measurement by indirect cuff sphygmomanometry. Am J Hypertens 1992; 5: 207-209.
4. Lemmer B, Portaluppi F. Chronopharmacology of cardiovascular diseases. In: Redfern PH, Lemmer B (eds). Physiology and Pharmacology of Biological Rhythms. Springer: Heidelberg, 1997, pp 251-298.
5. Sharma AM, Wittchen HU, Kirch W, Pittrow D, Ritz E, Göke B et al High prevalence and poor control of hypertension in primary care: cross-sectional study. J Hypertens 2004; 22: 479-486.
6. Stecklings UM, Stoppelhaar M, Sharma AM, Wittchen HU, Krause P, Küpper B et al. HYDRA: Possible determinants of unsatisfactory hypertension control in German primary care patients. Blood Press 2004; 13: 80-88.
7. Hansson L, Zanchetti A, Carruthers SG, Dahlöf B, Elmfeldt D, Julius S et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the hypertension optimal treatment (HOT) randomised trial. Lancet 1998; 351: 1755-1762.
8. ESH-ESC Task Force on the Management of Arterial Hypertension. 2007 ESH-ESC practice guidelines for the management of arterial hypertension. J Hypertens 2007; 25: 1751-1762.
9. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000; 342: 145-153.
10. Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U et al. Cardiovascular morbidity and mortality in the Losartan intervention for endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol. Lancet 2002; 359: 995-1003.
11. Hasford J, Schröder-Bernhardi D, Rottenkolber M, Kostev K, Dietlein G. Persistence with antihypertensive treatments: Results of a 3-year follow up cohort study. Eur J Clin Pharmacol 2007; e-pub ahead of print 14 August 2007.